| Project/Area Number |
24591973
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANI Tohru 滋賀医科大学, 医学部, その他(特任教授) (20179823)
KURUMI Yoshimasa 滋賀医科大学, 医学部, 教授 (70205219)
SHIMIZU Tomoharu 滋賀医科大学, 医学部, 助教 (70402708)
MIYAKE Tohru 滋賀医科大学, 医学部, その他(客員助教) (70581924)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 腫瘍免疫 / 免疫治療 / 癌ワクチン / T細胞補助刺激 / 細胞治療 / 養子免疫 / CTL / OX40 / B7DC / がん免疫治療 / がんワクチン / エフェクター細胞 / 補助刺激 / 癌免疫治療 |
|---|
| Outline of Final Research Achievements |
We have done the research to develop the efficient cancer-specific CTL therapy, which was to generate CTLs ex vivo and to transfer them into patients.
Cancer-specific CTLs were efficiently generated when T cells were cultured with a cancer antigen and OX40 costimulation that could enhance the effector T cell function. When these cancer-specific CTLs were adoptively transferred into the tumor-bearing mice pretreated with OX40 costimulation that could also inhibit the regulatory T cell function, CTLs could overcome immune tolerance condition, maintain its function, and finally eliminate tumor. IL-2 and/or B7-DC proved to be important molecules that could contribute to the generation of effective CTLs.
Human lymphocytes from the volunteers could generate antigen (HA)-specific CTLs when cultured with an antigen and OX40 stimulation. From these findings, we believe that cancer-specific CTL therapy treated with costimulatory molecules can be applied in a clinical setting in future.
|
